GLB1 and GM1 gangliosidosis: Consequently, gene therapies based on cisterna magna delivery of LYS-GM101 and PBGM01 and IV delivery of AAV9-GLB1 have been approved for clinical trials for type I and type II GM1 gangliosidosis [250,251].